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Abstract 
 
Objective: The present study aimed at comparing the prevalence of major psychiatric disorders including major 
depressive disorder, bipolar disorder, schizophrenia, and generalized anxiety disorder between performance-enhancing 
drug users and nonuser bodybuilders. Moreover, the prevalence of major psychiatric disorders in bodybuilders was also 
reported. 
Method: In this study, 453 athletes were recruited from Bushehr bodybuilding gyms from February to May 2015. A 
structured questionnaire was used to collect the participants’ information, including demographic characteristics, sports’ 
status and performance-enhancing drug use. According to the condition of performance-enhancing drug use, the 
participants were divided into current users, non-current users, and nonusers. The psychiatric status of the participants 
was evaluated using DSM-IV diagnostic criteria for major depressive disorder, bipolar disorder, generalized anxiety 
disorder, and schizophrenia. We also asked about the acute psychotic disturbances after using performance-enhancing 
drugs, alcohol use, and history of aggressive behavior in bodybuilders. Data were analyzed using one-way analysis of 
variance and chi-square tests.  
Results: Prevalence of major depressive disorder, bipolar disorder, schizophrenia, generalized anxiety disorder, and 
the overall prevalence of psychiatric disorders in the bodybuilders was 19.7%, 3.8%, 1.5%, 16.6%, and 26.7%, 
respectively. After using performance-enhancing drugs, 33% of the bodybuilders had experienced acute psychological 
disturbances. There were no significant differences between current, non-current, and nonuser bodybuilding athletes in 
the measured psychiatric disorders.  
Conclusion: Prevalence of psychiatric disorders was not significantly different in performance-enhancing drug users 
and nonusers. Thus, it can be concluded that performance-enhancing drugs do not increase the risk of psychiatric 
disorders in bodybuilders. 
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The advancing rate of performance-enhancing drugs 
(PED) abuse in many countries around the world poses 
the public health to serious problems and this issue is not 
well appreciated by the medical community or official 
authorities (1, 2). PED abuse, particularly anabolic 
steroids (AASs), can produce adverse effects on 
different body systems including endocrine system, 
reproductive system, liver, skin, cardiovascular system, 
and central nervous system (CNS) (3, 4). In spite of the 
numerous studies that assessed the somatic effects of 
AASs, only a few examined the psychiatric adverse 
effects of these agents (5). 
 
 
 
 
 
 
 
 
Studies have shown that the high doses of AASs may 
cause psychiatric disorders such as mood disorders (6). 
Moreover, it was revealed that AAS users develop acute 
psychiatric disturbances such as aggression and violence 
(7) and are more likely to use alcohol (8) or commit 
suicide (9). However, some studies have reported no 
mood changes after AAS administration (10). Therefore, 
it was proposed that psychological effects of PEDs may 
have considerable variability in athletes (11, 12). 
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Furthermore, there is limited information about the 
mental effects of the concurrent use of other agents 
such as stimulants in combination with AASs. 
Taken together, psychiatric side effects of PEDs, 
particularly AASs, in the bodybuilders is an important 
challenging issue. Moreover, most studies did not 
examine the psychiatric effects of the concurrent use of 
other drugs such as stimulants in addition to the AASs 
in bodybuilders (13). The present study aimed at 
comparing the prevalence of major psychiatric 
disorders including major depressive disorder, bipolar 
disorder, schizophrenia, and generalized anxiety 
disorder between male PED users and nonuser 
bodybuilders. We also reported the prevalence of 
psychiatric disorders in male bodybuilders. 
 
Materials and Methods 
Participants and Study Design 
Sample size (N = 474) was calculated via power and 
sample size calculator software (Version 3.1.2) by 
considering the power of 0.80, α of 0.05, P0 of 0.10, 
and P1 of 0.05. We randomly selected 11 bodybuilding 
clubs from Bushehr port and invited all athletes, who 
were present at the club. Males with regular training 
routines (minimum of 1 year and 4 hours/week) were 
eligible to participate in the study. Those with the 
history of drug abuse, psychoactive drug use, and 
chronic disease were excluded from the study. In our 
study, 453 male bodybuilders participated from 
February to May 2015 . 
All parts of the survey were in accordance with the 
Declaration of Helsinki and approved by the research 
ethics committee of Bushehr University of Medical 
Sciences. We presented all the details of the study and 
ensured the participants that all parts of the survey 
would remain confidential and would only be used 
collectively for the research purposes. After 
introducing all aspects of the survey, the participants 
were asked to sign written consent forms .  
Data Collection 
Before the initiation of the study, the validity and 
reliability of the study questionnaire were demonstrated 
by Waltz-Bausell (CVI = 0.83) and Cronbach (alpha = 
0.744) methods on a group of bodybuilders, who went 
to the university gym. The questionnaires were 
completed by a trained physician who had experience 
in psychiatric evaluation. The questionnaire was mostly 
obtained from Ip et al. (14) investigation and evaluated 
several characteristics of male bodybuilders in 3 
separate parts. In the first part, we recorded the 
demographic characteristics such as age, height, and 
weight. In the second part, we asked about sports’ 
status (recreational or professional), sports history, 
exercise schedule, and PEDs use (the age of first use, 
the type of PED, the period of use, and the length of 
PED cycles in each year). To confirm PED use, we 
assessed the follicular stimulating hormone (FSH) and 
luteinizing hormone (LH) by the chemiluminescence 
method using commercial kits (Roche, USA). Then, the 
athletes were classified according to the status of PEDs 
use. Athletes with lower than normal level of 
gonadotropins (lower than 1.0 MIU/ml for FSH and 
lower than 0.7 MIU/ml for LH) were categorized as 
current users. Athletes with a history of PED use within 
24 months and a normal level of FSH and LH were 
considered as non-current users, and those with normal 
level of gonadotropins and no history of PED use were 
considered as nonusers. Reasonably, this classification 
is only applicable for the AASs. In the third part, we 
asked about the family history and personal history of 
psychiatric disorders. Then, we evaluated the 
psychiatric status of the participants using DSM-IV 
diagnostic criteria for MDD, BD, GAD, and 
schizophrenia. Moreover, we asked about alcohol use, 
history of aggressive behavior, and acute psychotic 
disturbances after using PEDs (euphoria, irritability, 
mood swings, violent feelings, and hostility). 
Statistical Analysis  
Descriptive data were reported as mean ± SEM for the 
continuous data and number and percentage of the 
participants for the categorical data. We used Student’s 
t test and one-way analysis of variance (ANOVA) test 
for the continuous data, and chi-square test for the 
categorical data. Spearman test was used to assess the 
correlation between the variables. Statistical 
significance was set at 0.05 probability level.  We 
performed all statistical analyses using SPSS software 
for Windows, Version 23. 
 
Results 
Demographic and Sports Status of the Bodybuilder 
In the present study, 4.2% (n = 19) of the participants 
were current users, 47.5% (n = 215) non-current users, 
and 48.3% (n=219) nonuser athletes. Moreover, 79.4% 
of the participants reported AAS use, 49.6% stimulants, 
and 7.7% peptide hormones. The age, weight, and BMI 
of the 3 study groups were significantly different 
(Table 1). Post-hoc analysis showed that the age of 
current users (p=0.014) and non-users (p=0.010) were 
higher than the non-users. The BMI and weight of the 
non-current users were higher than the non-users 
(p=0.000). Moreover, the mean sports history (year) of 
current and noncurrent users were significantly higher 
than the nonuser athletes (Table 1). In addition, the 
exercise schedules of the 3 studied groups were 
significantly different (Table 1). Post-hoc analysis 
showed that the exercise schedule of current (p=0.008) 
and non-current   (p=0.008) users were more rigorous 
than the non-users. Table 1 also demonstrates sports 
status and characteristics of PED use in bodybuilders. 
The prevalence of MDD, BD, schizophrenia, GAD, 
and the overall prevalence of psychiatric disorders in 
the bodybuilders was 19.7%, 3.8%, 1.5%, 16.6%, and 
26.7%, respectively (table2Table 2). Furthermore, 
8.8% of all participants had a family history of 
psychiatric disorders. 
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Table1. The Demographic Variables, Sports Status, and Characteristics of Performance-Enhancing 
Drug Use in the Bodybuilders 
 
 
 
Current users 
(Mean ± SEM) 
Non-current users 
(Mean±SEM) 
Nonusers 
(Mean±SEM) 
F(df) p 
Age  30.42±1.46 27.82±0.42 25.95±0.48 7.02(2) 0.00 
Weight  82.32±2.55 83.14±0.89 77.68±0.78 11.06(2) 0.00 
BMI
†
 26.74±0.81 26.32±0.26 24.84±0.23 10.15(2) 0.00 
Sport history 
(year) 
8.37±1.25 6.77±0.37 4.74±0.30 11.45(2) 0.00 
Exercise routines 
(hour/week) 
8.74±0.86 8.80±0.27 7.64±0.20 6.10(2) 0.00 
Age of first use 
(year) 
24.84±1.34 23.34±0.38 - 1.27(1) 0.26 
Length of PED
‡
 
use cycles 
(day/year) 
74.74±9.14 59.42±2.58 - 2.86(1) 0.09 
History of PED 
use (year) 
3.26±0.58 3.23±0.28 - 0.00(1) 0.98 
† BMI: body mass index, ‡ PED: performance-enhancing drug 
 
 
Table2. Prevalence of Psychiatric Disorders in the Male Bodybuilders 
 
 Current PED users 
(%) 
Non-current PED 
users (%) 
Nonusers 
(%) 
Total 
(%) 
χ2(df) P-value 
MDD 15.8 22.3 17.3 16.6 0.88(2) 0.64 
BD 0 4.7 3.2 3.8 0.92(2) 0.63 
Schizophrenia  0 1.9 1.4 1.5 0.36(1) 1.00 
GAD 15.8 19.5 13.7 16.6 0.16(1) 1.00 
OPP 26.3 30.7 22.8 26.7 0.16(1) 0.80 
The data were analyzed using Chi-square test. The p-value less than 0.05 was considered to be significant.  
 
Table3. Prevalence of Violence and Alcohol Use in the Male Bodybuilders 
 
 Current PED users (%) Non-current PED users (%) Nonusers (%) Total (%) 
Alcohol use 52.6* 44.2* 26.5 36 
Violence  36.8* 15.4* 5.5 11.7 
*p value of <0.05 compared to the nonusers 
 
Table4. The comorbidity of Violence and Alcohol Use with Psychiatric Disorders in the Male 
Bodybuilders 
 
 
  
Violence 
(%) 
χ2 p-value Alcohol use (%) χ2 p-value 
Major depressive 
disorder 
Healthy 8.2 
21.44 0.000 
31.9 
13.61 0.000  
25.8 52.8 
Depressed 
Bipolar disorder (BD) 
Healthy 11 
5.36 0.037 
35.6 
0.94 0.440  
29.4 47.1 
Patient 
Schizophrenia 
Healthy 11.2 
6.68 0.038 
35.4 
3.88 0.104  
42.9 71.4 
Patient 
Generalized anxiety 
disorder 
Healthy 9 
16.17 0.000 
32.5 
11.75 0.001  
25.3 53.3 
Patient 
Overall prevalence of 
psychiatric disorders 
Healthy 7.5 
20.92 0.000 
31.0 
13.27 0.000  
23.1 49.6 
Patient 
Data were analyzed using Chi-square test. p-value lower than 0.05 was considered to be significant. 
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In our study, 33% of PED users had experienced acute 
psychological disturbances after using these agents. 
The experience of acute psychological effect of PEDs 
was different in bodybuilders with psychiatric disorders 
compared to healthy athletes (χ2 = 3.91, df = 1, p = 
0.05). The prevalence of psychotic disturbances after 
using PEDs was significantly different in the athletes, 
who used various classes of PEDs (χ2 = 13.24, df = 5, p 
= 0.02). Moreover, the highest level of psychotic 
disturbance after using PEDs was related to the athletes 
who had used 3 classes of these agents (AASs, 
stimulants, and peptides) (75%). Moreover, the 
prevalence of psychotic disturbances after using AASs 
was higher than the non-AAS users although the 
difference was not statistically significant (χ2 = 4.17, df 
= 1, p = 0.06). Similarly, the prevalence of psychotic 
disturbances after using stimulant agents (33.9%) was 
not significantly different from non-stimulant users 
(32.2%) (χ 2 = 0.08, df = 1, p = 0.78).  
There were no significant differences between the 
current, non-current, and nonuser bodybuilders in the 
measured psychiatric disorders (Table 2). The type of 
PEDs abused by the athletes had no association with 
MDD (χ2(df) = 8.97(10), p = 0.56), schizophrenia 
(χ2(df) = 0.38(10), p = 1.00), and GAD (χ2(df) = 
7.30(10), p = 2.00), and the overall prevalence of 
psychiatric disorders (χ2(df) = 8.03(10), p = 0.16). 
However, the type of PED class had a correlation with 
BD (χ2(df) = 31.64(10), p = 0.00). Those athletes, who 
used all classes of PEDs together, had a higher rate of 
BD (33.3%). Furthermore, anxiety was more prevalent 
only among stimulant agent users (25.5%), and mood 
disorders were more seen among athletes who had used 
3 classes of PEDs (44.4%). 
PED: performance-enhancing drugs, MDD: major 
depressive disorder, BD: bipolar disorder, GAD: 
generalized anxiety disorder, OPP: the overall 
prevalence of psychiatric disorders  
Family history and personal history of psychiatric 
disorders had no correlation with the initiation of PED 
use (rs = 0.07, p>0.05 and rs = 0.08, p>0.05, 
respectively). However, the length of PED use cycles 
(day/year) was associated with MDD (rs = 0.14, p = 
0.03), GAD (rs = 0.20, p = 0.00) and the overall 
prevalence of psychiatric disorders (rs = 0.19,  
p = 0.00). Moreover, the FSH level was associated with 
MDD (rs = -0.15, p<0.05) and violence (rs = -0.17, 
p<0.05), while there was no association between FSH 
and other psychiatric disorders.  
Our study revealed that the prevalence of violence and 
alcohol use were higher in the current and non-current 
athletes compared with the nonuser athletes (χ2 = 23.35, 
df = 2, p = 0.00 and χ2 = 17.14, df = 2, p = 0.00, 
respectively) (Table4). Moreover, the prevalence of 
violence in athletes with MDD, BD, schizophrenia, and 
GAD was higher than the healthy athletes (Table 4). 
Moreover, the prevalence of alcohol use was higher in 
the athletes with MDD and GAD compared with the 
non-MDD and non-GAD athletes (Table 4).  
 
Discussion 
The present study revealed a high prevalence of 
psychiatric disorders among bodybuilders. There are 
limited research about the prevalence of psychiatric 
disorders in the athletes (15). However, it was shown 
that mental disorders are as common in sports as they 
are within the general population (15). Our study may 
imply that the prevalence of psychiatric disorders in 
bodybuilders was higher than the general Iranian 
population. When we comparing our study to a study 
about the prevalence of psychiatric disorders in the 
Iranian general population (16), we found that the 
overall prevalence of psychiatric disorders in the male 
bodybuilders may be higher than the general 
population. In line with our study, it was shown that the 
prevalence of mood disorders was higher in the 
bodybuilders compared with the non-athlete controls 
(17). We only considered male athletes, while other 
studies on the general population included both male 
and female participants . 
Our study demonstrated that the prevalence of 
psychiatric disorders was not significantly different 
between PED abuser (current and non-current) and 
non-abuser athletes. In this regard, there are some 
inconsistencies between the studies about the effects of 
PEDs, particularly AASs, on mental health (3, 18). In 
agreement with our study, it was found that PEDs, 
particularly AASs, exerted minimal long-term effects 
on the mood status (19). Furthermore, a study by 
Angoorani and Halabchi (20) revealed that mental 
health had no correlation with the AAS abuse in 
Iranian bodybuilders. On the other hand, some reports 
have shown that the prevalence of mood and anxiety 
disorders were higher in AASs abusers (5). In this 
regard, a Swedish research has shown that AASs ex-
users were more engaged in seeking psychiatric 
treatment compared with the nonuser athletes (21). 
These inconsistencies may be related to the 
interindividual variation in both condition of androgen 
excess (22) and deprivation (23). Taken together, it is 
not completely clear whether AASs play a causative 
role in the development of long-term psychiatric 
disorders, but some evidences imply that AASs abusers 
may be at a greater risk for mood disorders (10) . 
About one third of the bodybuilders in our study had 
experienced psychotic disturbances after using PEDs. 
Moreover, our study may imply that the prevalence of 
psychotic disturbances after using PEDs is higher in 
those athletes with psychiatric disorders. Furthermore, 
it found that using high doses of methyltestosterone 
raises the chance of acute mood changes in the male 
normal volunteers (11). Also, our study showed that 
using different classes of PEDs simultaneously may be 
another risk factor for the PED-induced acute psychotic 
disturbances. This may be related to synergistic effects 
of AASs and stimulants on the CNS. In this regard, it 
was shown that stimulant agents can produce 
psychoactive adverse effects such as anxiety, 
irritability, and paranoia (24). In addition, some studies 
have proposed that AAS abusers exhibit acute 
Ostovar, Haerinejad,  Akbarzadeh, et al. 
 224 Iranian J Psychiatry 12: 4, October 2017 ijps.tums.ac.ir 
psychotic symptoms such as hypomania, irritability, 
and aggressiveness during exposure to these agents 
(25). Therefore, administration of these 2 classes of 
PEDs may increase the probability of acute psychiatric 
side effects of these agents  . 
The length of PED use had a correlation with MDD 
and GAD in the bodybuilding athletes. Some studies 
have implied that mood changes regarding PED use 
may be related to deprivation from AASs (26). In 
contrast, our study may imply that PED use but not 
deprivation may be in association with the behavioral 
disturbances, mainly because increasing the length of 
PED cycles (day/year) use had increased the likelihood 
of psychiatric disorders. 
The prevalence of aggressive behavior was higher in 
the PED abusers compared with the nonuser athletes. 
Moreover, our study revealed that the FSH level has a 
reverse correlation with aggressive behavior. This may 
imply that higher level of AASs may have a correlation 
with aggressive behavior. Also, in several other studies, 
it was revealed that AASs had profound effects on the 
aggression (27) and high dose of AASs elicit 
aggressive behavior in animals and humans (27, 28). 
However, the correlation of AAS use and aggressive 
behavior may be confounded by the psychiatric 
disorder in bodybuilders. Our study showed that the 
likelihood of aggressive behavior in the athletes with at 
least one psychiatric disorder was about 3 times than 
that of healthy athletes. Therefore, it seems that other 
studies that did not measure psychiatric disorders in the 
AAS abusers, might have overestimated the aggressive 
effects of AASs. 
Our study showed that the likelihood of alcohol use 
was higher among PED users. AAS have been involved 
with alcohol and other illicit drugs (29). In contrast, 
some investigations did not report any association 
between alcohol and PED use (14). Similar to the 
aggressive effects, we reported higher rates of alcohol 
use among athletes with at least one psychiatric 
disorder. Again, our study may imply that the higher 
prevalence of alcohol use among PED users may be 
confounded by the presence of psychiatric disorders. 
Therefore, it is better to distinguish the effects of 
psychiatric disorders when comparing the correlation 
of AASs and alcohol administration. 
 
Limitation 
We could not identify the current users of stimulants 
and peptide hormones. However, athletes almost 
always use other classes of PEDs together with AASs. 
Moreover, the classification of participants to non-
current and nonusers mainly relied on the personal 
reports and some athletes might have hidden their 
status of PED use. Therefore, we suggest further 
studies on the psychiatric effects of PEDs in ex-users 
and users with established PED use background. 
 
Conclusion 
Taken together, the prevalence of psychiatric disorders 
in bodybuilders is high and comparable (if not higher) 
with the general population. However, the prevalence 
of psychiatric disorders was not significantly different 
in PED user and nonuser bodybuilders. Therefore, it 
can be concluded that performance-enhancing drugs do 
not increase the risk of psychiatric disorders in 
bodybuilders. 
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